Open AccessCommentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”)
Author(s) -
Mayer Fishman
Publication year - 2019
Publication title -
translational andrology and urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.721
H-Index - 27
eISSN - 2223-4691
pISSN - 2223-4683
DOI - 10.21037/tau.2019.09.19
Subject(s) - pembrolizumab , urothelial cancer , medicine , oncology , chemotherapy , cytotoxic t cell , cancer , antibody , bladder cancer , immunotherapy , immunology , biology , in vitro , biochemistry